J. Mcgrath, S. Saha, D. Chant, and J. Welham, Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality, Epidemiologic Reviews, vol.30, issue.1, pp.67-76, 2008.
DOI : 10.1093/epirev/mxn001

D. Dickinson, V. N. Iannone, C. M. Wilk, and J. M. Gold, General and specific cognitive deficits in schizophrenia, Biological Psychiatry, vol.55, issue.8, pp.826-833, 2004.
DOI : 10.1016/j.biopsych.2003.12.010

&. Awad and . Voruganti, Measuring Quality of Life in Patients with Schizophrenia, PharmacoEconomics, vol.56, issue.7, pp.183-195, 2012.
DOI : 10.2165/11594470-000000000-00000

L. Boyer, Measuring quality of life in patients with schizophrenia:an overview, Expert Review of Pharmacoeconomics & Outcomes Research, vol.13, issue.3, pp.343-349, 2013.
DOI : 10.1586/erp.13.15

A. O. Adelufosi, A. Ogunwale, O. Abayomi, and J. Mosanya, Socio-demographic and clinical correlates of subjective quality of life among Nigerian outpatients with schizophrenia, Psychiatry Research, vol.209, issue.3, pp.320-325, 2013.
DOI : 10.1016/j.psychres.2012.12.027

C. Hsiao, M. Hsieh, C. Tseng, S. Chien, and C. Chang, Quality of life of individuals with schizophrenia living in the community: relationship to socio-demographic, clinical and psychosocial characteristics, Journal of Clinical Nursing, vol.10, issue.15-16, pp.2367-2376, 2012.
DOI : 10.1111/j.1365-2702.2012.04067.x

L. Boyer, K. Baumstarck, E. Guedj, and P. Auquier, What???s wrong with quality-of-life measures? A philosophical reflection and insights from neuroimaging, Expert Review of Pharmacoeconomics & Outcomes Research, vol.14, issue.6, pp.767-769, 2014.
DOI : 10.1586/14737167.2014.950236

M. Hamer and Y. Chida, Life satisfaction and inflammatory biomarkers: The 2008 Scottish Health Survey1, Japanese Psychological Research, vol.276, issue.2, pp.133-139, 2011.
DOI : 10.1111/j.1468-5884.2011.00460.x

A. C. Nowakowski, Chronic inflammation and quality of life in older adults: a cross-sectional study using biomarkers to predict emotional and relational outcomes, Health and Quality of Life Outcomes, vol.6, issue.3, p.141, 2014.
DOI : 10.1186/s12955-014-0141-0

D. M. Cummings, D. E. King, A. G. Mainous, and C. Protein, C-Reactive Protein, Antiinflammatory Drugs, and Quality of Life in Diabetes, Annals of Pharmacotherapy, vol.106, issue.11, p.1593, 2003.
DOI : 10.1056/NEJM199704033361401

B. J. Miller, B. Gassama, D. Sebastian, P. Buckley, and A. Mellor, Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects, Biological Psychiatry, vol.73, issue.10, pp.993-999, 2013.
DOI : 10.1016/j.biopsych.2012.09.007

B. J. Miller, P. Buckley, W. Seabolt, A. Mellor, and B. Kirkpatrick, Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects, Biological Psychiatry, vol.70, issue.7, pp.663-671, 2011.
DOI : 10.1016/j.biopsych.2011.04.013

J. Flatow, P. Buckley, and B. J. Miller, Meta-Analysis of Oxidative Stress in Schizophrenia, Biological Psychiatry, vol.74, issue.6, pp.400-409, 2013.
DOI : 10.1016/j.biopsych.2013.03.018

B. J. Miller, N. Culpepper, and M. H. Rapaport, C-Reactive Protein Levels in Schizophrenia, Clinical Schizophrenia & Related Psychoses, vol.7, issue.4, pp.223-230, 2014.
DOI : 10.3371/CSRP.MICU.020813

A. O. Akanji, J. U. Ohaeri, S. Al-shammri, and H. Fatania, Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients, Psychiatry Research, vol.169, issue.1, pp.56-61, 2009.
DOI : 10.1016/j.psychres.2008.06.010

X. Fan, Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia, Psychiatry Research, vol.149, issue.1-3, pp.267-271, 2007.
DOI : 10.1016/j.psychres.2006.07.011

M. H. Fawzi, M. M. Fawzi, M. M. Fawzi, and N. S. Said, C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia, Psychiatry Research, vol.190, issue.1, pp.91-97, 2011.
DOI : 10.1016/j.psychres.2011.05.010

F. Dickerson, C. Stallings, A. Origoni, J. Boronow, and R. Yolken, C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia, Schizophrenia Research, vol.93, issue.1-3, pp.261-265, 2007.
DOI : 10.1016/j.schres.2007.03.022

D. Lasi?, Metabolic syndrome and inflammation markers in patients with schizophrenia and recurrent depressive disorder, Psychiatr. Danub, vol.26, pp.214-219, 2014.

A. Sicras-mainar, J. Rejas-gutiérrez, R. Navarro-artieda, and M. Blanca-tamayo, C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice, European Psychiatry, vol.28, issue.3, pp.161-167, 2013.
DOI : 10.1016/j.eurpsy.2011.07.003

. American-psychiatric-association, Diagnostic and statistical manual-text revision (DSM-IV-TRim, 2000.

T. F. Heatherton, L. T. Kozlowski, R. C. Frecker, and K. Fagerström, The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire, Addiction, vol.36, issue.9, pp.1119-1127, 1991.
DOI : 10.1016/0306-4603(90)90009-M

J. B. Saunders, O. G. Aasland, T. F. Babor, J. R. De-la-fuente, and M. Grant, Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II, Addiction, vol.i, issue.6, pp.791-804, 1993.
DOI : 10.1111/j.1360-0443.1993.tb02093.x

S. R. Kay, L. A. Opler, and A. Fiszbein, Significance of positive and negative syndromes in chronic schizophrenia, The British Journal of Psychiatry, vol.149, issue.4, pp.439-448, 1986.
DOI : 10.1192/bjp.149.4.439

C. Lançon, G. Reine, P. M. Llorca, and P. Auquier, Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS), Acta Psychiatrica Scandinavica, vol.158, issue.3, pp.237-243, 1999.
DOI : 10.1016/0920-9964(90)90005-R

J. A. Lieberman, Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1223, 2005.
DOI : 10.1056/NEJMoa051688

J. M. Meyer, Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study, Biological Psychiatry, vol.66, issue.11, pp.1013-1022, 2009.
DOI : 10.1016/j.biopsych.2009.06.005

A. Gupta, G. Dadheech, D. Yadav, P. Sharma, and S. Gautam, Metabolic Issues in Schizophrenic Patients Receiving Antipsychotic Treatment, Indian Journal of Clinical Biochemistry, vol.99, issue.3, pp.196-201, 2014.
DOI : 10.1007/s12291-013-0415-z

P. Auquier, Toward Meeting the Needs of Homeless People with Schizophrenia: The Validity of Quality of Life Measurement, PLoS ONE, vol.24, issue.10, p.79677, 2013.
DOI : 10.1371/journal.pone.0079677.s001

K. Baumstarck, Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment, Schizophrenia Research, vol.147, issue.1, pp.58-67, 2013.
DOI : 10.1016/j.schres.2013.03.008

L. Boyer, The development of the S-QoL 18: A shortened quality of life questionnaire for patients with schizophrenia, Schizophrenia Research, vol.121, issue.1-3, pp.241-250, 2010.
DOI : 10.1016/j.schres.2010.05.019

A. Caqueo-urízar, L. Boyer, M. Boucekine, and P. Auquier, Spanish cross-cultural adaptation and psychometric properties of the Schizophrenia Quality of Life short-version questionnaire (SQoL18) in 3 middle-income countries: Bolivia, Chile and Peru, Schizophrenia Research, vol.159, issue.1, pp.136-143, 2014.
DOI : 10.1016/j.schres.2014.08.013

T. A. Pearson, Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association, Circulation, vol.107, issue.3, pp.499-511, 2003.
DOI : 10.1161/01.CIR.0000052939.59093.45

A. Wysoki?ski, A. Margulska, D. Strzelecki, and I. K?oszewska, Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder, Nordic Journal of Psychiatry, vol.22, issue.5, 2014.
DOI : 10.1111/dom.12156

F. Dickerson, C-reactive protein is elevated in schizophrenia, Schizophrenia Research, vol.143, issue.1, pp.198-202, 2013.
DOI : 10.1016/j.schres.2012.10.041

J. Van-os, S. Kapur, and . Schizophrenia, Schizophrenia, The Lancet, vol.374, issue.9690, pp.635-645, 2009.
DOI : 10.1016/S0140-6736(09)60995-8
URL : https://hal.archives-ouvertes.fr/hal-01382569

J. A. Morozink, E. M. Friedman, C. L. Coe, and C. Ryff, Socioeconomic and psychosocial predictors of interleukin-6 in the MIDUS national sample., Health Psychology, vol.29, issue.6, pp.626-635, 2010.
DOI : 10.1037/a0021360

D. J. Brotman, S. H. Golden, and I. S. Wittstein, The cardiovascular toll of stress, The Lancet, vol.370, issue.9592, pp.1089-1100, 2007.
DOI : 10.1016/S0140-6736(07)61305-1

M. Hamer and A. Steptoe, Association Between Physical Fitness, Parasympathetic Control, and Proinflammatory Responses to Mental Stress, Psychosomatic Medicine, vol.69, issue.7, pp.660-666, 2007.
DOI : 10.1097/PSY.0b013e318148c4c0
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.547.7044

M. Berk, So depression is an inflammatory disease, but where does the inflammation come from?, BMC Medicine, vol.79, issue.1, p.200, 2013.
DOI : 10.1186/1741-7015-11-200

M. Pantell, Social Isolation: A Predictor of Mortality Comparable to Traditional Clinical Risk Factors, American Journal of Public Health, vol.103, issue.11, pp.2056-2062, 2013.
DOI : 10.2105/AJPH.2013.301261

Y. C. Yang, M. K. Mcclintock, M. Kozloski, and T. Li, Social Isolation and Adult Mortality, Journal of Health and Social Behavior, vol.64, issue.2, pp.182-202, 2013.
DOI : 10.1037/0033-295X.107.3.411
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3998519

C. J. Donoho, E. M. Crimmins, and T. Seeman, Marital Quality, Gender, and Markers of Inflammation in the MIDUS Cohort, Journal of Marriage and Family, vol.26, issue.1, pp.127-141, 2013.
DOI : 10.1111/j.1741-3737.2012.01023.x

D. A. Sbarra, Marriage Protects Men from Clinically Meaningful Elevations in C-Reactive Protein: Results from the, National Social Life, Health, and Aging Project Psychosom. Med, vol.71, pp.828-835, 2009.

L. Boyer, Quality of life is predictive of relapse in schizophrenia, BMC Psychiatry, vol.30, issue.6, 2013.
DOI : 10.2165/11633640-000000000-00000

R. Dantzer, J. C. O-'connor, G. G. Freund, R. W. Johnson, and K. W. Kelley, From inflammation to sickness and depression: when the immune system subjugates the brain, Nature Reviews Neuroscience, vol.17, issue.1, pp.46-56, 2008.
DOI : 10.1038/nrn2297

R. Dantzer and K. W. Kelley, Twenty years of research on cytokine-induced sickness behavior, Brain, Behavior, and Immunity, vol.21, issue.2, pp.153-160, 2007.
DOI : 10.1016/j.bbi.2006.09.006

T. L. Gruenewald, S. Cohen, K. A. Matthews, R. Tracy, and T. Seeman, Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study, Social Science & Medicine, vol.69, issue.3, pp.451-459, 2009.
DOI : 10.1016/j.socscimed.2009.05.018

R. A. Pollitt, Cumulative life course and adult socioeconomic status and markers of inflammation in adulthood, Journal of Epidemiology & Community Health, vol.62, issue.6, pp.484-491, 2008.
DOI : 10.1136/jech.2006.054106

L. A. Bazzano, J. He, P. Muntner, S. Vupputuri, and P. K. Whelton, Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States, ACC Current Journal Review, vol.12, issue.5, pp.891-897, 2003.
DOI : 10.1016/j.accreview.2003.08.037

H. H. Hermsdorff, M. Á. Zulet, B. Puchau, and J. A. Martínez, Central Adiposity Rather Than Total Adiposity Measurements Are Specifically Involved in the Inflammatory Status from Healthy Young Adults, Inflammation, vol.116, issue.3, pp.161-170, 2011.
DOI : 10.1007/s10753-010-9219-y

D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling, and E. F. Wouters, Systemic Effects of Smoking, Chest, vol.131, issue.5, pp.1557-1566, 2007.
DOI : 10.1378/chest.06-2179

D. Heredia, F. P. Gómez-martínez, S. Marcos, and A. , Obesity, inflammation and the immune system, Proceedings of the Nutrition Society, vol.10, issue.02, pp.332-338, 2012.
DOI : 10.1017/S0007114507691909

B. Singh and T. K. Chaudhuri, Role of C-reactive protein in schizophrenia: An overview, Psychiatry Research, vol.216, issue.2, pp.277-285, 2014.
DOI : 10.1016/j.psychres.2014.02.004

L. Boyer, Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: A structural equation modeling approach, Psychoneuroendocrinology, vol.50, pp.95-105, 2014.
DOI : 10.1016/j.psyneuen.2014.07.019

L. Boyer, Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia, Psychiatry Research, vol.210, issue.2, pp.381-386, 2013.
DOI : 10.1016/j.psychres.2013.06.020

L. Boyer, Insight into illness, neurocognition and quality of life in schizophrenia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.36, issue.2, pp.271-276, 2012.
DOI : 10.1016/j.pnpbp.2011.10.008

A. W. Tolman and M. M. Kurtz, Neurocognitive Predictors of Objective and Subjective Quality of Life in Individuals With Schizophrenia: A Meta-Analytic Investigation, Schizophrenia Bulletin, vol.38, issue.2, pp.304-315, 2012.
DOI : 10.1093/schbul/sbq077